DrugPatentWatch Database Preview

Details for Patent: 9,375,410

« Back to Dashboard

Which drugs does patent 9,375,410 protect, and when does it expire?

Patent 9,375,410 protects AMRIX and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 9,375,410

Title:	Modified release dosage forms of skeletal muscle relaxants
Abstract:	A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration-time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
Inventor(s):	Venkatesh; Gopi M. (Vandalia, OH), Clevenger; James M. (Vandalia, OH)
Assignee:	ADARE PHARMACEUTICALS, INC. (Lawrenceville, NJ)
Application Number:	14/496,890
Patent Claim Types: see list of patent claims	Use; Formulation; Dosage form; Composition;

Drugs Protected by US Patent 9,375,410

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-001	Feb 1, 2007		RX	Yes	No						RELIEF OF MUSCLE SPASM
Teva Pharms Intl	AMRIX	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	021777-002	Feb 1, 2007		RX	Yes	Yes						RELIEF OF MUSCLE SPASM

Non-Orange Book US Patents Family Members for Patent 9,375,410

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,399,025	Modified release dosage forms of skeletal muscle relaxants
7,790,199	Modified release dosage forms of skeletal muscle relaxants
7,387,793	Modified release dosage forms of skeletal muscle relaxants
8,877,245	Modified release dosage forms of skeletal muscle relaxants

International Family Members for US Patent 9,375,410

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2005048996